CRISPR Therapeutics AG

CRSP is entrenched in a Stage 4 decline with confirmed Support Failure and persistent lower highs/lower lows. Despite a long-term uptrend, medium- and short-term biases are decisively bearish, reinforced by down-sloping EMAs, distribution volume, and lack of exhaustion despite extreme oversold. Under the SPEC strategy, we take a Sell Now posture, selling into any rallies toward the EMA resistance zone.

• ↑FDA approval of Casgevy for sickle cell and β-thalassemia expands U.S. base by ~5,500 pediatric patients
• ↑Bank of America, HC Wainwright, Piper Sandler uphold buy ratings and $110 price target
• ↓Q2 2026 projected EPS of -$1.12 and revenue of $7.4 M indicate ongoing losses